Back

Efficacy and Safety of a Pharmaco-Invasive Strategy versus Primary Angioplasty in ST-Elevation Myocardial Infarction: The EARLY-MYO Trial

27 August 2017 (14:15 - 14:30)
Organised by:
Congress Presentation Part of: Late-Breaking Science in PCI 2 Infarction acute phase STEMI ESC Premium Access ESC Congress 2017

About the speaker

Photo
Professor Ben HE

Shanghai Chest Hospital, Shanghai (China)

5 More presentations in this session

Presentation thumbnail
The Bivalirudin versus Heparin in non-ST and ST-segment elevation myocardial infarction in patients on modern antiplatelet therapy in SWEDEHEART
Professor D. Erlinge (Lund, SE)
Slides Video
Presentation thumbnail
Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes - TROPICAL-ACS - Trial
Professor D. Sibbing (Munich, DE)
Slides Video
Presentation thumbnail
RE-DUAL PCI : Dual Antithrombotic Therapy with Dabigatran After Percutaneous Coronary Intervention in Patients with Atrial Fibrillation
Professor C. Cannon (Boston, US)
Slides Video
Presentation thumbnail
Have we reached the bottom line in mortality after Acute Myocardial Infarction? Changes over 20 years in patient characteristics, management, and 6-month outcomes in the FAST-MI programme: 1995-2015
Professor N. Danchin (Paris, FR)
Slides Video
Presentation thumbnail
Improvement in FFR predicts 2 years outcome after PCI. A FAME 2 Sub-Analysis.
Doctor S. Fournier (Lausanne, CH)
Slides Video

Access the full session

Session thumbnail
Late-Breaking Science in PCI 2

The Event

Event poster

ESC Congress 2017

27 August 2017 14:15 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources